Jordyn Sava

In the phase 3 CLEAR study, lenvatinib combined with pembrolizumab continued to elicit deep and durable tumor response among patients with advanced clear cell renal cell carcinoma.

In an interview, John Diaz, MD, discusses updates to the cervical cancer treatment landscape and where the field is moving to potentially eradicate this disease in the United States.

The safety, tolerability, pharmacokinetics, immunogenicity, and tumor response of KVA12123 alone and with pembrolizumab are being evaluated in a phase 1/2 study for patients with advanced solid tumors.

In an interview with Targeted Oncology, Dan T. Vogl, MD, MSCE, discussed a phase 1 study which evaluated modakafusp alfa for the treatment of patients with relapsed or refractory multiple myeloma.

A phase 1a/1b trial of IMGS-001 in patients with locally advanced or metastatic solid tumors is ongoing at The University of Texas MD Anderson Cancer Center in Houston, Texas.

A post hoc analysis of overall survival and progression-free survival support the use of avelumab with best supportive care as a standard of care for patients with urothelial carcinoma.

The phase 3 ALINA study of alectinib is the first to show an improvement in its primary end point of disease-free survival among patients with early-stage resected ALK-positive non–small cell lung cancer.

Major pathological response and pathological complete response data from the phase 3 RATIONALE 315 study in NSCLC will be presented at the European Society for Medical Oncology Congress 2023.

In an interview with Targeted Oncology, Rohan Garje, MD, discussed current treatment options for patients with prostate cancer and the role of PARP inhibitors.

New data from the phase 3 RATIONALE 305 trial of tislelizumab with chemotherapy show potential of the combination for patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma.

A fast track designation has been granted to DOC1021 by the FDA for the treatment of patients with glioblastoma multiforme.

Findings from a phase 2 study show that sequential minimal residual disease assessment is a powerful prognostic tool in patients with mantle cell lymphoma.

While a notable difference in the occurrence of adverse events was seen between patients treated with maximal tumor debulking and standard systemic therapy vs systemic therapy alone, health-related quality-of-life and fatigue scales showed no substantial differences over time.

In an interview with Targeted Oncology, Heather Wakelee, MD, discussed what community oncologists should know about the newly approved combination of pembrolizumab with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of pembrolizumab monotherapy as post-surgical adjuvant treatment.

The FDA has approved pembrolizumab in the perioperative setting for resectable stage II, IIIA, or IIIB non–small cell lung cancer.

A phase 1 trial of TERN-701 for chronic myeloid leukemia plans to start patient screening in December 2023, with initial data expected to be released in the second half of 2024.

In an interview with Targeted Oncology, Rupesh Kotecha, MD, discusses the background of this phase 1 study and current options for patients with brain metastases.

This regulatory decision follows the recent FDA approval of encorafenib plus binimetinib for adult patients with metastatic non-small cell lung cancer harboring a BRAF V600E mutation.

In a phase 1b trial, AVID200 demonstrated limited toxicity and improved symptom benefit when administered at 3 doses levels.

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

Interim results from a phase 2 trial shows LSAM-PTX may provide therapeutic benefits for patients with locally advanced pancreatic cancer.

A prospective, multicenter trial continues to recruit patients with brain metastases to evaluate the real-world and patient-reported outcomes of surgically targeted radiation therapy.

Encorafenib combined with binimetinib is now an FDA-approved option for patients with BRAF V600E-mutated non-small cell lung cancer.

SLS009 represents a promising solution for patients with acute myeloid leukemia, addressing a significant unmet medical need. Top-line data on the agent are expected by the end of the year.

Results from the EVEREST study do not support the adjuvant use of everolimus for patients with renal cell carcinoma following surgery.

A first-in-human trial is assessing the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of STX-721 as a monotherapy for patients with non–small cell lung cancer with EGFR exon 20 insertion mutations.

At median follow-ups of 9.2 and 9.9 months in a phase 1b/2 study, the confirmed objective response rate with the TPST-1120 triplet was 30% vs 13.3% in the control arm, respectively.

The next-generation diagnostic tool is approved for companion diagnostic use with selpercatinib for select solid locally advanced and metastatic tumors.

Data from the PROpel study support the FDA’s approval of olaparib plus abiraterone for patients with metastatic castration-resistant prostate cancer.

A statistically significant overall survival benefit was observed with perioperative pembrolizumab in the phase 3 KEYNOTE-671 trial for patients with stage II, IIIA or IIIB non–small cell lung cancer.